Wall Street Zen cuts CVS Health stock rating to Buy by CVS Health stock facts

Published on 10/26/2026 at 11:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wall Street Zen cut CVS Health to Buy on October 19, 2026. CVS Health stock costs EUR 83.77, 0.08 percent below the Xetra close in Germany.

CVS Health events and valuation

An analyst rating moved from strong-buy to buy on October 19, 2026.
Second-quarter revenue reached USD 106.1 billion, up 7.3 percent year over year.
CVS Health stock trades at EUR 83.77 at 11:05 a.m. CET at Lang & Schwarz on October 26, 2026, 0.08 percent below the Xetra close of October 23, 2026.
CVS Health will discuss third-quarter results on November 4, 2026.

Draufsicht-Arrangement aus Aktienzertifikat, Stethoskop, Medikamenten und Finanzunterlagen auf Marmor — CVS Health Corp. Flatlay-Arrangement mit Aktienzertifikat, Stethoskop und pharmazeutischen Medikamenten, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health stock (ISIN US1266501006) was trading at EUR 83.77 at Lang & Schwarz on October 26, 2026 at 11:05 a.m. CET, 0.08 percent below the Xetra close of October 23, 2026 at EUR 83.84. On October 19, 2026, MarketBeat reported that Wall Street Zen cut its CVS Health rating from strong-buy to buy.

Rating change meets stronger results

The rating change came after CVS Health reported a stronger second quarter. According to Ticker Scout, revenue for the quarter ended June 30, 2026, rose 7.3 percent year over year to USD 106.1 billion. Adjusted earnings per share increased to USD 2.58 from USD 1.81 in the same quarter of 2025, while GAAP diluted earnings per share reached USD 2.31 from USD 0.80.

The company also raised its full-year 2026 adjusted earnings-per-share guidance to USD 7.90-8.10 from USD 7.30-7.50. Operating cash flow guidance increased to at least USD 11.5 billion from at least USD 9.5 billion, according to the same filing summary.

Three milestones frame the story

On May 6, 2026, CVS Health reported first-quarter revenue of USD 100.4 billion and adjusted earnings per share of USD 2.57, according to Ticker Scout. On August 5, 2026, second-quarter revenue reached USD 106.1 billion and adjusted earnings per share reached USD 2.58. On October 19, 2026, Wall Street Zen lowered its rating from strong-buy to buy, as reported by MarketBeat.

What dates matter next?

CVS Health is scheduled to discuss third-quarter 2026 results on November 4, 2026, at 8:00 a.m. ET. The date was announced by CVS Health on October 5, 2026. Board appointee Teresa Heitsenrether is scheduled to join the board on November 18, 2026, according to Ticker Scout.

Medical costs remain the test

The second-quarter figures show why the November report matters: revenue growth and higher adjusted earnings per share came alongside a Health Care Benefits medical benefit ratio of 87.4 percent, down from 89.9 percent a year earlier. That comparison points to improved insurance economics, but the next report will show whether the improvement held into the second half.

Stock level and investor context

CVS Health's primary listing is on the NYSE under ticker CVS. The stock's market capitalization was USD 119.5 billion on October 26, 2026, while its 52-week range was USD 69.51 to USD 110.68. At EUR 83.77, the Lang & Schwarz quote was EUR 0.07 below the Xetra close of October 23, 2026 at EUR 83.84. The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.